Keyphrases
Randomized Controlled Trial
100%
Obesity
100%
Diabetes
100%
Treatment Trials
100%
Clozapine
100%
Metabolic Indices
100%
Exenatide
100%
Usual Care
30%
Hemoglobin A1c (HbA1c)
30%
Weight Gain
30%
Glucagon-like
20%
Metformin
20%
Clinical Endpoints
20%
Glucagon-like peptide-1 Receptor (GLP-1R)
20%
Type 2 Diabetes Mellitus (T2DM)
10%
Blood Pressure
10%
Trial Participants
10%
Waist Circumference
10%
Change in Weight
10%
No Significant Difference
10%
Fasting Plasma Glucose
10%
Weight Loss
10%
Dysregulation
10%
Once-weekly
10%
A1 Receptor
10%
Receptor Agonist
10%
Extended Release
10%
Associated Weights
10%
Metformin Use
10%
Collecting Information
10%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Clozapine
100%
Exendin 4
100%
Hemoglobin A1c
30%
Metformin
30%
Non Insulin Dependent Diabetes Mellitus
10%
Glucagon Like Peptide 1 Receptor Agonist
10%
Glucagon-Like Peptide-1
10%